A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

BACKGROUND: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumours. METHODS: Sunitinib was initially admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Boven, E, Massard, C, Armand, J P, Tillier, C, Hartog, V, Brega, N M, Countouriotis, A M, Ruiz-Garcia, A, Soria, J C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965864/
https://www.ncbi.nlm.nih.gov/pubmed/20717111
http://dx.doi.org/10.1038/sj.bjc.6605852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965864/
https://www.ncbi.nlm.nih.gov/pubmed/20717111
http://dx.doi.org/10.1038/sj.bjc.6605852

Ejemplares similares